The biotech sector outperformed the S&P 500 last year – and further strong performance could lie ahead thanks in part to the tax break for companies that repatriate funds from overseas, which could stimulate mergers and acquisitions. As the author of today’s article acknowledges, “That could be big news for some of the smaller players that have promising drugs in the pipeline.” He proceeds to highlight three biotech stocks with catalysts that give them massive upside potential – including a potential acquisition target. For more, CLICK HERE.